TCW Group Inc. Boosts Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

TCW Group Inc. lifted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,400 shares of the company’s stock after purchasing an additional 3,300 shares during the period. TCW Group Inc. owned 0.40% of Fulgent Genetics worth $2,279,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of FLGT. Point72 Asset Management L.P. purchased a new stake in Fulgent Genetics in the third quarter worth about $5,854,000. JPMorgan Chase & Co. lifted its holdings in Fulgent Genetics by 113.2% in the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock worth $7,346,000 after buying an additional 179,477 shares during the period. Invenomic Capital Management LP lifted its holdings in Fulgent Genetics by 98.9% in the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after buying an additional 124,185 shares during the period. Peapod Lane Capital LLC purchased a new stake in Fulgent Genetics in the fourth quarter worth about $2,022,000. Finally, Barclays PLC increased its stake in shares of Fulgent Genetics by 22.6% during the third quarter. Barclays PLC now owns 174,855 shares of the company’s stock valued at $3,800,000 after purchasing an additional 32,250 shares in the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on FLGT. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th. Piper Sandler decreased their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th.

Fulgent Genetics Stock Up 1.8 %

Shares of FLGT opened at $16.75 on Tuesday. The company has a market capitalization of $512.33 million, a P/E ratio of -3.03 and a beta of 1.39. The firm has a 50 day moving average of $17.61 and a 200 day moving average of $19.71. Fulgent Genetics, Inc. has a twelve month low of $15.99 and a twelve month high of $25.50.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.